Experience Matters,
Trust in RhoGAM

  • RhoGAM was the first anti-D product available1
  • RhoGAM helped set the standards and clinical practice guidelines that are still followed today
  • Only RhoGAM has been consistently available across four decades with no interruptions in supply1

Year after year, RhoGAM is a reliable choice.

Below are a few of RhoGAM’s milestones over the last 50 years

1968 >
  • RhoGAM approved
1979 >
  • MICRhoGAM approved
1984 >
  • ACOG releases antepartum protocols
1985 >
  • Pre-filled, ready-to-use syringe available
1991 >

New indications approved for:

> PUBS

> CVS

1997 >
  • RhoGAM Ultra-Filtered approved
  • Viresolve 180 Ultrafiltration added to remove potential viruses present, including HAV
2001 >
  • Safety Shield added
  • Thimerosal removed
2007 >
  • RhoGAM Ultra-Filtered PLUS approved
  • West Nile virus removal capability validated
2012 >
  • Kedrion Biopharma acquired RhoGAM and MICRhoGAM
2013 >
  • Medicaid Drug Rebate Program enrollment

 

Reference:
1. Data on File. Kedrion Biopharma Inc.

 

Important Safety Information

RhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (300 μg) and MICRhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (50 μg) are indicated for the prevention of Rh immunization, including during and after pregnancy and other obstetrical conditions or incompatible transfusion of Rh-positive blood.

RhoGAM® and MICRhoGAM® are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent.

RhoGAM® and MICRhoGAM® are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration.

RhoGAM® and MICRhoGAM® contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. Patients who receive RhoGAM® and MICRhoGAM® for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction.

You are encouraged to report adverse events of prescription drugs to the FDA.
Visit www.fda.gov/Safety/MedWatch/ or call 1-800-FDA-1088.

Click here for the RhoGAM Full Prescribing Information

This site is intended for residents of the US only.

 

Back to top